scholarly journals In Vitro Activity of BL-S640 Against Gram-Negative Bacilli and Staphylococcus aureus Compared with Activity of Four Other Semisynthetic Cephalosporins

1976 ◽  
Vol 9 (3) ◽  
pp. 422-432 ◽  
Author(s):  
A. Vuye ◽  
J. Pijck ◽  
H. Soep
Keyword(s):  
Staphylococcus Aureus ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Gram Negative ◽  
And Staphylococcus Aureus

scholarly journals Prevalence and regional variation in meticillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial

2007 ◽  
Vol 56 (9) ◽  
pp. 1189-1193 ◽  
Author(s):  
Debra A. Goff ◽  
Michael J. Dowzicky
Keyword(s):  
United States ◽  
Staphylococcus Aureus ◽  
New Hampshire ◽  
Regional Variation ◽  
Vitro Activity ◽  
Surveillance Study ◽  
In Vitro Activity ◽  
Gram Negative ◽  
The Usa

The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) is a surveillance study established in 2004 to monitor the activity of tigecycline, the first glycylcycline, and comparator agents [β-lactams (including penicillins, cephalosporins and carbapenems), glycopeptides, tetracyclines, fluoroquinolones and oxazolidinones] against Gram-positive and Gram-negative pathogens worldwide. This report examines 1692 isolates of Staphylococcus aureus collected in the continental United States between January 2004 and September 2005. Meticillin-resistant S. aureus (MRSA) accounted for 52.0 % of isolates. Prevalence of MRSA by state ranged from 12.5 % in New Hampshire to 100 % in Kentucky. All isolates were susceptible to tigecycline, linezolid and vancomycin. In vitro, tigecycline was potent against both meticillin-susceptible S. aureus (MSSA) (MIC50 and MIC90=0.12 μg ml−1) and MRSA (MIC50=0.12 μg ml−1; MIC90=0.25 μg ml−1). Only a single isolate was resistant to three or more antimicrobial classes. Ninety-six isolates (5.7 %) were susceptible to the complete antimicrobial panel.

scholarly journals In Vitro Activity of HSR-903, a New Oral Quinolone, against Bacteria Causing Respiratory Infections

1999 ◽  
Vol 43 (7) ◽  
pp. 1767-1768 ◽  
Author(s):  
Akira Watanabe ◽  
Yutaka Tokue ◽  
Hiroshi Takahashi ◽  
Tohru Kikuchi ◽  
Takao Kobayashi ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Streptococcus Pneumoniae ◽  
Respiratory Infections ◽  
The Other ◽  
Vitro Activity ◽  
Respiratory Pathogens ◽  
In Vitro Activity ◽  
Gram Negative ◽  
Resistant Strains

ABSTRACT The in vitro activity of HSR-903, an oral quinolone, against 196 recent clinical isolates of respiratory pathogens was evaluated. HSR-903 was 2 to 32 times more active than ofloxacin, ciprofloxacin, and sparfloxacin against Staphylococcus aureus, including methicillin-resistant strains, and Streptococcus pneumoniaeand was at least as active as the other quinolones against gram-negative pathogens.

Sign in / Sign up

Export Citation Format

Share Document